newsfilter
← Latest News
Business Wire·

Cortexyme to Present New GAIN Trial Data at AD/PD 2022

New data expands evidence base of role of P. gingivalis in Alzheimer's disease Discussion to include new biomarker results and correlations between biomarkers and clinical outcomes Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical